News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
In direct opposition to a petition raised by GPhA (Generic Pharmaceutical Association) and Novartis, AbbVie, Genentech and Amgen are all looking for the US FDA to call for new non-proprietary names for biosimilars.
GSK’s Eperzan (albiglutide) has become the first approved drug to use the Veltis half-life extension technology and, according to Novozymes, may make it a strong competitor in the GLP-1 agonist market.
Researchers are developing a cellulose filter paper they claim is at least as effective at removing viruses from biopharmaceutical production streams as currently available industrial systems.
French mAb developers that hire Cobra Biologics stand to benefit from tax breaks after the French Ministry of Higher Education and Research (MESR) named the CMO as a preferred provider.